Portal de Periódicos da CAPES

SYMPATHETIC OVERACTIVITY AND CORONARY RISK IN HYPERTENSION

1997; Wiley; Volume: 11; Issue: S1 Linguagem: Inglês

10.1111/j.1472-8206.1997.tb00882.x

1472-8206

John Amerena, Stevo Julius,

Heart Rate Variability and Autonomic Control

Fundamental & Clinical PharmacologyVolume 11, Issue S1 p. 78s-81s SYMPATHETIC OVERACTIVITY AND CORONARY RISK IN HYPERTENSION John Amerena, John Amerena University of Michigan, 3918 Taubman center 48109–0356, Ann Arbor, MI, USASearch for more papers by this authorStevo Julius, Stevo Julius University of Michigan, 3918 Taubman center 48109–0356, Ann Arbor, MI, USASearch for more papers by this author John Amerena, John Amerena University of Michigan, 3918 Taubman center 48109–0356, Ann Arbor, MI, USASearch for more papers by this authorStevo Julius, Stevo Julius University of Michigan, 3918 Taubman center 48109–0356, Ann Arbor, MI, USASearch for more papers by this author First published: 26 August 2009 https://doi.org/10.1111/j.1472-8206.1997.tb00882.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Julius S, Jamerson K: Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken-and-egg’ question. J Hypertens 1994; 12: 495–502. 2 Amerena J and Julius S. The rRole of the Autonomic Nervous System in Hypertension. Hypertens Res 1995 18: 2 99–110. 3 Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. The Tecumseh Blood Pressure Study. JAMA 1990 264 (3) 354–358. 4 Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–357. 5 Pyorala K, Savolainen E, Kaukola S, Haapakoski J: Plasma insulin as a coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2 year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl 1985; 701: 38–52. 6 Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO: Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21(5): 618–623. 7 Stout RW, Bierman EL, Ross R: Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975; 36: 319–327. 8 Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW, Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989; 256: H126–H131. 9 Deibert DC, DeFronzo RA: Epinephrine-induced insulin resistance in man. J Clin Invest 1980; 65: 717–721. 10 Zeman RJ, Ludemann R, Easton TG, Etlinger JD: Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta-2-receptor agonist. Am J Physiol 1988; 254: E726–E732. 11 Julius S, Pascual AV, Abbrecht P, London R: Effect of beta-adrenergic blockade on plasma volume in human subjects. Proc Soc Exp Biol Med 1972; 140: 982–985. 12 Cohn JN: Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci 1966; 30: 267–278. 13 Smith S, Julius S, Jamerson K, Amerena J and Schork N. Hematacrit levels and physiologic factors in Tecumseh, Michigan. J Hypertens 1994; 12:4 455–461. 14 Kjeldsen SE, Gjesdal K, Eide I, Aakesson I, Amundsen R, Foss OP, Leren P: Increased beta-thromboglobulin in essential hypertension: Interactions between arterial plasma adrenaline, platelet function and blood lipids. Acta Med Scand 1983; 213: 369–373. 15 Julius S, Pascual AV, London R: Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971; 44: 413–418. 16 Simpson P: Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response. J Clin Invest 1983; 72: 732–738. 17 Schelling P, Fischer H, Gantlen D: Angiotensin and cell growth: a link to cardiac hypertrophy? J Hypertens 1991; 9: 3–15. 18 Kannel WB, Gordon T, Castelli WP, Margolis JR: Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 1970; 72: 813–822. 19 Egan B, Panis R, Hinderliter A, Schork N, Julius S: Mechanism of increased alpha-adrenergic vasoconstriction in human essential hypertension. J Clin Invest 1987; 80: 812–817. 20 Brush JE, Cannon RO, Schenke WH, Bonow R, Leon M, Maron B, Epstein S: Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988; 319 (20): 1302–1307. Volume11, IssueS1December 1997Pages 78s-81s ReferencesRelatedInformation